<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02151838</url>
  </required_header>
  <id_info>
    <org_study_id>TRCS PMTCT</org_study_id>
    <nct_id>NCT02151838</nct_id>
  </id_info>
  <brief_title>The Thai Red Cross Society Prevention of Mother-To-Child Transmission of HIV (TRCS PMTCT) Program</brief_title>
  <official_title>The Thai Red Cross AIDS Research Centre</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thai Red Cross AIDS Research Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thai Red Cross AIDS Research Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and the efficacy of Highly Active Anti-Retroviral Treatment (HAART) for&#xD;
      the Prevention of Mother-To-Child Transmission of HIV (PMTCT)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To describe characteristics of HIV-infected pregnant women who request HAART from the&#xD;
           Thai Red Cross Society PMTCT (TRCS PMTCT) program&#xD;
&#xD;
        2. To study adverse pregnancy outcomes among HIV-infected pregnant women who receive HAART&#xD;
&#xD;
        3. To study adverse events in infants born to women who receive HAART during pregnancy&#xD;
&#xD;
        4. To evaluate risk factors for HAART-related toxicities and for perinatal HIV transmission&#xD;
&#xD;
        5. To establish the pilot model of care for HIV-infected pregnant women in middle income&#xD;
           country&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2008</start_date>
  <completion_date type="Actual">July 2021</completion_date>
  <primary_completion_date type="Actual">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HIV-infected pregnant women</measure>
    <time_frame>18 months</time_frame>
    <description>Choose to start HAART according to protocol and do not want to receive antiretroviral treatment provided by the other health care systems</description>
  </primary_outcome>
  <enrollment type="Actual">250</enrollment>
  <condition>HIV-infected Pregnant Women Who Request HAART From the TRCSPMTCT</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will be HIV-infected pregnant women who request HAART from the TRCS&#xD;
        PMTCT program. These pregnant women will be under the care of the health care teams in 30&#xD;
        hospitals throughout Thailand which have registered with the TRCS PMTCT program since April&#xD;
        2004&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Volunteers meeting all of the following criteria will be considered eligible for enrollment&#xD;
        in the study:&#xD;
&#xD;
          1. HIV-infected pregnant women (as defined by the hospital)&#xD;
&#xD;
          2. Choose to start HAART according to protocol and do not want to receive antiretroviral&#xD;
             treatment provided by the other health care systems&#xD;
&#xD;
          3. Understand the study and sign informed consent form. Persons who cannot read will have&#xD;
             the consent form read to them by a study staff and they can give informed consent by&#xD;
             using thumb print.&#xD;
&#xD;
          4. Availability for follow-up for the planned study duration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Volunteers meeting any of the following criteria will be excluded from the study:&#xD;
&#xD;
        1.Persons who have a history of a medical or psychiatric disorder by interview and physical&#xD;
        examination according to standard practices, that in the judgment of the treating&#xD;
        physician, would interfere with or serve as a contraindication to adherence to the study&#xD;
        protocol or ability to give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Thai Red Cross AIDS Research Centre</name>
      <address>
        <city>Pathum Wan</city>
        <state>Bangkok</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 28, 2014</study_first_submitted>
  <study_first_submitted_qc>May 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2014</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-infected pregnant women who request HAART from the TRCSPMTCT</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

